Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
Yanez A, Dimitroff A, Bremner P, Rhee CS, Luscombe G, Prillaman BA, Johnson N. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol. 2016 Jan 1;7(4):183-92. doi: 10.2500/ar.2016.7.0185
McKenna SP, Doward LC. How should we measure quality of life in ankylosing spondylitis? Rheumatol Pract. 2008;6(2):12-4.